Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
The UK’s Publicly Funded Vaccines Market
23 November 2010
The OHE has just published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by…
Access to Orphan Drugs in the EU
21 October 2010
Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr…
Which English Hospital is Best at Hips?
29 September 2010
Earlier this month, the first set of data on post operative patient reported outcomes (PROMs) was published by the Department of Health (DH). For the first…
Costs and Bariatric Surgery in England
23 September 2010
Obesity is an increasing challenge in England, as elsewhere. OHE has completed a study that examines PCT practice and the cost savings that could accrue if…
Value Based Pricing in the UK
7 September 2010
Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article…
Defining Benefit Through Willingness to Pay
24 August 2010
Since 2007, new medications may be paid for by the statutory health insurance funds (GKV) in Germany only if they are cost-effective. Willingness-to-pay analyses can be…
Comparing Economic Appraisal Guides in England
10 August 2010
Debate continues about the methods that the UK’s NICE uses in its appraisals of medical technologies, including whether effects beyond the NHS should be considered using…
Limits to Using QALYs in Cancer
3 August 2010
QALY measures have become important tools in valuing health interventions so that resource allocations can be made. Current methods, however, may not adequately capture QALYs for…
Reminder: Willingness-to-Pay Seminar
5 July 2010
Willingness-to-Pay for a New Pharmaceutical: Is it Worth the Money? Whose Money? During this OHE Lunchtime Seminar, Prof Peter Zweifel, University of Zurich, will discuss the findings…